Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Declining incidence of dementia: A national registry-based study over 20 years

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Inflammatory biomarkers in Alzheimer's disease plasma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Alberto Lleó
  • Daniel Alcolea
  • Pablo Martínez-Lage
  • Philip Scheltens
  • Lucilla Parnetti
  • Judes Poirier
  • Anja H Simonsen
  • Marcel M Verbeek
  • Pedro Rosa-Neto
  • Rosalinde E R Slot
  • Mikel Tainta
  • Andrea Izaguirre
  • Babette L R Reijs
  • Lucia Farotti
  • Magda Tsolaki
  • Rik Vandenbergue
  • Yvonne Freund-Levi
  • Frans R J Verhey
  • Jordi Clarimón
  • Juan Fortea
  • Lutz Frolich
  • Isabel Santana
  • José Luis Molinuevo
  • Sylvain Lehmann
  • Pieter J Visser
  • Charlotte E Teunissen
  • Henrik Zetterberg
  • Kaj Blennow
Vis graf over relationer

Introduction: Within-person trajectories of cerebrospinal fluid (CSF) biomarkers in Alzheimer's disease (AD) are not well defined. Methods: We included 467 subjects from the BIOMARKAPD study with at least two serial CSF samples. Diagnoses were subjective cognitive decline (n = 75), mild cognitive impairment (n = 128), and AD dementia (n = 110), and a group of cognitively unimpaired subjects (n = 154) were also included. We measured baseline and follow-up CSF levels of total tau (t-tau), phosphorylated tau (p-tau), YKL-40, and neurofilament light (NfL). Median CSF sampling interval was 2.1 years. Results: CSF levels of t-tau, p-tau, NfL, and YKL-40 were 2% higher per each year of baseline age in controls (P <.001). In AD, t-tau levels were 1% lower (P <.001) and p-tau levels did not change per each year of baseline age. Longitudinally, only NfL (P <.001) and YKL-40 (P <.02) increased during the study period. Discussion: All four CSF biomarkers increase with age, but this effect deviates in AD for t-tau and p-tau.

OriginalsprogEngelsk
TidsskriftAlzheimer's & dementia : the journal of the Alzheimer's Association
Vol/bind15
Udgave nummer6
Sider (fra-til)742-753
Antal sider12
ISSN1552-5260
DOI
StatusUdgivet - jun. 2019

Bibliografisk note

Copyright © 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

ID: 58214755